JPMorgan Starts ResMed (RMD) at Neutral
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
JPMorgan initiated coverage on ResMed (NYSE: RMD) with a Neutral rating and a price target of $64.
Shares of ResMed closed at $64.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades ResMed (RMD) to Overweight
- BofA/Merrill Lynch Starts Almost Family (AFAM) at Neutral
- Mercury Computer (MRCY) PT Raised to $30 at Jefferies Following 2Q Report
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!